Qiagen’s (QGEN) Buy Rating Reaffirmed at Commerzbank

Commerzbank reaffirmed their buy rating on shares of Qiagen (NASDAQ:QGEN) in a research note issued to investors on Friday morning.

Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. restated a neutral rating on shares of Qiagen in a research report on Tuesday, November 7th. Evercore ISI assumed coverage on shares of Qiagen in a research report on Wednesday, January 3rd. They set an outperform rating and a $35.00 target price on the stock. BidaskClub upgraded shares of Qiagen from a sell rating to a hold rating in a research report on Wednesday, December 20th. Zacks Investment Research lowered shares of Qiagen from a hold rating to a sell rating in a research report on Thursday, November 9th. Finally, Cowen reiterated a hold rating and issued a $34.00 price objective on shares of Qiagen in a research report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. Qiagen has an average rating of Hold and an average target price of $34.63.

Shares of Qiagen (NASDAQ QGEN) traded up $0.31 during midday trading on Friday, hitting $32.87. 1,831,029 shares of the company’s stock traded hands, compared to its average volume of 1,010,000. The stock has a market cap of $7,520.00, a price-to-earnings ratio of 84.28, a P/E/G ratio of 1.81 and a beta of 1.10. Qiagen has a 52 week low of $27.51 and a 52 week high of $36.34. The company has a quick ratio of 4.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.68.

Qiagen (NASDAQ:QGEN) last issued its earnings results on Monday, November 6th. The company reported $0.32 EPS for the quarter, hitting the consensus estimate of $0.32. The company had revenue of $364.00 million for the quarter, compared to analyst estimates of $363.42 million. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. The business’s revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.29 EPS. equities research analysts forecast that Qiagen will post 1.25 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. Fox Run Management L.L.C. purchased a new stake in shares of Qiagen in the 3rd quarter worth about $753,000. OxFORD Asset Management LLP boosted its position in shares of Qiagen by 6.7% in the 3rd quarter. OxFORD Asset Management LLP now owns 81,216 shares of the company’s stock worth $2,558,000 after buying an additional 5,116 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Qiagen in the 3rd quarter worth about $10,110,000. AXA boosted its position in shares of Qiagen by 5.0% in the 3rd quarter. AXA now owns 405,798 shares of the company’s stock worth $12,783,000 after buying an additional 19,268 shares in the last quarter. Finally, Cubist Systematic Strategies LLC boosted its position in shares of Qiagen by 27.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 16,208 shares of the company’s stock worth $543,000 after buying an additional 3,519 shares in the last quarter. Institutional investors and hedge funds own 61.39% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Qiagen’s (QGEN) Buy Rating Reaffirmed at Commerzbank” was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3148028/qiagens-qgen-buy-rating-reaffirmed-at-commerzbank.html.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.